Drug intelligence / Profile preview

PEDQ

Development stage: Preclinical
Lead developer: Reber Genetics
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PEDQ is a recombinant protein subunit vaccine developed by Reber Genetics for the prevention of Porcine Epidemic Diarrhea (PED) in swine. The vaccine is produced using a proprietary subunit technology platform that applies principles of cancer immunotherapy to animal health, presenting specific Porcine Epidemic Diarrhea virus (PEDV) antigens to induce a protective immune response. PED is a highly contagious viral disease characterized by severe enteric distress, vomiting, and high mortality rates in neonatal piglets, posing a significant economic threat to the swine industry. As of 2019, a New Drug Application (NDA) for PEDQ was filed in Taiwan.

Other names: PEDPED virus subunit vaccinePorcine Epidemic Diarrhea virus subunit vaccine

Beyond the preview

Go deeper on PEDQ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEDQ.

Explore the full profile